<?xml version="1.0" encoding="UTF-8"?>
<iati-activities version="2.03">
 <iati-activity default-currency="USD" hierarchy="1" humanitarian="0" iati-activities:version="2.03" xml:lang="EN" xmlns:iati-activities="http://d-portal.org/xmlns/iati-activities">
  <iati-identifier>SE-0-SE-29-2019-04596-998-12250</iati-identifier>
  <reporting-org ref="SE-0" secondary-reporter="0" type="10">
   <narrative xml:lang="EN">Sweden</narrative>
  </reporting-org>
  <title>
   <narrative xml:lang="EN">Adverse effects of pre-exposure prophylaxis against HIV on mucosal immunology in male adolescents</narrative>
   <narrative xml:lang="SV">Biverkningar vid f&#xF6;rebyggande behandling mot HIV p&#xE5; slemhinnans immunologi hos yngre m&#xE4;n</narrative>
  </title>
  <description type="1">
   <narrative xml:lang="SV">Ett viktigt omr&#xE5;de f&#xF6;r HIV-f&#xF6;rebyggande &#xE4;r HIV pre-exponeringsprofylax (PrEP), en potentiellt livr&#xE4;ddande och kostnadseffektiv metod f&#xF6;r att behandla individer under h&#xF6;griskperioder i sitt liv. Med tanke p&#xE5; att PrEP har visat sig vara en effektiv &#xE5;tg&#xE4;rd f&#xF6;r att f&#xF6;rhindra HIV-infektion i v&#xE4;st v&#xE4;rlden, f&#xF6;rv&#xE4;ntas PrEP anv&#xE4;ndningen snart &#xF6;ka i afrikanska l&#xE4;nder som har en h&#xF6;g f&#xF6;rekomst av HIV-infektion bland ungdomar och vuxna.&#xC4;ven d&#xE5; det &#xE4;r br&#xE5;dskande att PrEP b&#xF6;rjar anv&#xE4;ndas &#xF6;ver hela Afrika s&#xF6;der om Sahara, PrEP implementeringen har varit l&#xE5;ngsam och kontinuitet i behandlingen suboptimal. F&#xF6;r att optimera effektiviteten, spridning och tillg&#xE5;ngen till PrEP f&#xF6;r unga personer &#xE4;r det viktigt att f&#xF6;rst&#xE5; de sociala hindren f&#xF6;r PrEP-anv&#xE4;ndning och PrEP-effekten (antingen biologiskt eller beteendem&#xE4;ssigt) i denna grupp. Det finns dessutom en brist p&#xE5; PrEP-klinisk effektivitet och farmakokinetiska data p&#xE5; unga kvinnor och m&#xE4;n.S&#xF6;kandena i detta projekt deltar i en studie - CHAPS - som fick st&#xF6;d fr&#xE5;n EU-EDCTP-programmet. Studien av ungdomar i Sydafrika och Uganda i CHAPS-projektet kommer att bidra till att f&#xF6;rst&#xE5; ungdomars s&#xE5;rbarheter och hinder f&#xF6;r att f&#xF6;rhindra hiv-infektion, minimera hinder f&#xF6;r att f&#xE5; tillg&#xE5;ng till h&#xE4;lsov&#xE5;rdssystem som &#xE4;r n&#xF6;dv&#xE4;ndiga f&#xF6;r f&#xF6;rebyggande st&#xF6;d och identifiera en ny och f&#xF6;renklad PrEP-regim f&#xF6;r unga m&#xE4;n som ut&#xF6;var penetrerande sex. Detta kommer att leda till nya strategier f&#xF6;r att engagera ungdomar i hiv-f&#xF6;rebyggande &#xE5;tg&#xE4;rder som f&#xF6;rhoppningsviss kommer att minska hiv-incidensen i Sahara Afrika. Inom ramen f&#xF6;r CHAPS-projektet kommer f&#xF6;rhudsprover att erh&#xE5;llas fr&#xE5;n unga m&#xE4;n (13-29 &#xE5;r) som f&#xE5;r PrEP f&#xF6;re frivillig omsk&#xE4;rning; en kontrollgrupp kommer inte att ta PrEP. HIV-negativa m&#xE4;n (n = 112) kommer att rekryteras fr&#xE5;n kliniker i Sydafrika (n = 56) och Uganda (n = 56).Studier om den kliniska och biologiska&#xA0;PrEP s&#xE4;kerheten hos ungdomar saknas &#xE4;nnu. Det &#xE4;r mycket viktigt att bed&#xF6;ma att PrEP-administrering, hos ungdomar under utveckling, inte leder till immunologiska f&#xF6;r&#xE4;ndringar i k&#xF6;nsorganens slemhinna, inklusive uttrycket av molekyler som spelar en nycker roll i det inflammatoriska svaret.CHAPS-budgeten t&#xE4;cker vissa laboratoriearbeten som ska genomf&#xF6;ras med v&#xE4;rdefulla f&#xF6;rhudprover som samlas in genom studien. Det beh&#xF6;vs dock mer ekonomiska resurser f&#xF6;r att maximera laboratoriearbetet och vi hoppas p&#xE5; st&#xF6;d fr&#xE5;n detta VR-program f&#xF6;r att kunna 1) m&#xE4;ta inflammationscytokiner och v&#xE4;vnadsintegritet i f&#xF6;rhud efter PrEP administrering in vivo och 2) utv&#xE4;rdera eventuell st&#xF6;rning av inflammationsgener och cytokiner vid ex vivo profylax av f&#xF6;rhud som exponerats f&#xF6;r HIV.De f&#xF6;reslagna studierna &#xE4;r nya och kommer att bidra avsev&#xE4;rt f&#xF6;r att hantera kunskapsbrister i PrEP-f&#xE4;ltet. Laboratoriearbetet kommer att &#xE4;ga rum vid Karolinska Institutet och Imperial College of London i samarbete med en partner i Uganda.</narrative>
   <narrative xml:lang="EN">One key area of impact for HIV prevention is HIV pre-exposure prophylaxis (PrEP), a potentially life-saving and cost-effective intervention to treat individuals during high risk periods of their life. Considering that PrEP has been proven to be an effective measure to prevent HIV infection it is expected that its use will soon increase in African countries which have a high incidence of HIV infection among adolescents and adults.The applicant and co-applicants participate in an EDCTP funded project (CHAPS; 2018-2021), which is the first multi-country dosing/regime efficacy study for on-demand PrEP in two African countries, Uganda and South Africa. The CHAPS budget covers some laboratory work to be conducted with valuable foreskin specimens collected through the study. More funds are however needed to maximize the laboratory work and we hope in support from this VR call:To measure inflammation cytokines and tight junctions&#x2019; integrity in foreskins upon PrEP administration in vivo.To evaluate the possible perturbation of inflammation genes and pathways upon ex vivo PEP exposure of foreskin.The proposed&#xA0;studies are novel and will contribute significantly to address knowledge gaps in the PrEP&#xA0;field.HIV negative men (n=112) (13- 29 years) will be recruited from clinics in South Africa (n=56) and Uganda (n=56). The laboratory work of this application will take place at the Karolinska Institutet and Imperial college of London in collaboration with a partner in Uganda.</narrative>
  </description>
  <participating-org ref="SE-0" role="1" type="10">
   <narrative xml:lang="EN">Sweden</narrative>
  </participating-org>
  <participating-org ref="SE-29" role="3" type="10">
   <narrative xml:lang="EN">The Swedish Research Council</narrative>
  </participating-org>
  <participating-org ref="51000" role="4" type="80">
   <narrative xml:lang="EN">University, college or other teaching institution, research institute or think-tank</narrative>
  </participating-org>
  <activity-status code="2"></activity-status>
  <activity-date iso-date="2020-01-01" type="1"></activity-date>
  <activity-date iso-date="2023-12-31" type="3"></activity-date>
  <contact-info>
   <organisation>
    <narrative xml:lang="EN">The Swedish Research Council</narrative>
   </organisation>
   <telephone>+46 8 546 44 000</telephone>
   <email>vetenskapsradet@vr.se</email>
   <website>www.vr.se</website>
   <mailing-address>
    <narrative xml:lang="EN">Box 1035, 101 38 Stockholm, Sweden</narrative>
   </mailing-address>
  </contact-info>
  <recipient-region code="998" percentage="100" vocabulary="1">
   <narrative xml:lang="EN">Developing countries, unspecified</narrative>
  </recipient-region>
  <sector code="122" percentage="100" vocabulary="2">
   <narrative xml:lang="EN">Basic Health</narrative>
  </sector>
  <sector code="12250" percentage="100" vocabulary="1">
   <narrative xml:lang="EN">Infectious disease control</narrative>
  </sector>
  <tag code="3.3" vocabulary="3">
   <narrative xml:lang="EN">3.3 - By 2030, end the epidemics of AIDS, tuberculosis, malaria and neglected tropical diseases and combat hepatitis, water-borne diseases and other communicable diseases.</narrative>
   <narrative xml:lang="SV">3.3 - Senast 2030 utrota epidemierna av aids, tuberkulos, malaria och f&#xF6;rsummade tropiska sjukdomar samt bek&#xE4;mpa hepatit, vattenburna sjukdomar och andra smittsamma sjukdomar.</narrative>
  </tag>
  <policy-marker code="5" significance="0" vocabulary="1">
   <narrative xml:lang="EN">Aid Targeting the Objectives of the Convention on Biological Diversity</narrative>
  </policy-marker>
  <policy-marker code="8" significance="0" vocabulary="1">
   <narrative xml:lang="EN">Aid Targeting the Objectives of the Convention to Combat Desertification</narrative>
  </policy-marker>
  <policy-marker code="7" significance="0" vocabulary="1">
   <narrative xml:lang="EN">Aid Targeting the Objectives of the Framework Convention on Climate Change - Adaptation</narrative>
  </policy-marker>
  <policy-marker code="6" significance="0" vocabulary="1">
   <narrative xml:lang="EN">Aid Targeting the Objectives of the Framework Convention on Climate Change - Mitigation</narrative>
  </policy-marker>
  <policy-marker code="2" significance="0" vocabulary="1">
   <narrative xml:lang="EN">Aid to Environment</narrative>
  </policy-marker>
  <policy-marker code="11" significance="0" vocabulary="1">
   <narrative xml:lang="EN">Disability</narrative>
  </policy-marker>
  <policy-marker code="10" significance="0" vocabulary="1">
   <narrative xml:lang="EN">Disaster Risk Reduction(DRR)</narrative>
  </policy-marker>
  <policy-marker code="1" significance="1" vocabulary="1">
   <narrative xml:lang="EN">Gender Equality</narrative>
  </policy-marker>
  <policy-marker code="3" significance="0" vocabulary="1">
   <narrative xml:lang="EN">Participatory Development/Good Governance</narrative>
  </policy-marker>
  <policy-marker code="9" significance="2" vocabulary="1">
   <narrative xml:lang="EN">Reproductive, Maternal, Newborn and Child Health (RMNCH)</narrative>
  </policy-marker>
  <policy-marker code="4" significance="0" vocabulary="1">
   <narrative xml:lang="EN">Trade Development</narrative>
  </policy-marker>
  <collaboration-type code="1"></collaboration-type>
  <default-flow-type code="10"></default-flow-type>
  <default-finance-type code="110"></default-finance-type>
  <default-aid-type code="D02" vocabulary="1"></default-aid-type>
  <default-tied-status code="4"></default-tied-status>
  <budget>
   <period-start iso-date="2020-01-01"></period-start>
   <period-end iso-date="2020-12-28"></period-end>
   <value currency="USD" value-date="2020-01-01">189466.4321313398</value>
  </budget>
  <budget>
   <period-start iso-date="2021-01-01"></period-start>
   <period-end iso-date="2021-12-28"></period-end>
   <value currency="USD" value-date="2021-01-01">170688.5131980412</value>
  </budget>
  <budget>
   <period-start iso-date="2022-01-01"></period-start>
   <period-end iso-date="2022-12-28"></period-end>
   <value currency="USD" value-date="2022-01-01">128460.319011477</value>
  </budget>
  <transaction>
   <transaction-type code="2"></transaction-type>
   <transaction-date iso-date="2019-11-28"></transaction-date>
   <value currency="USD" value-date="2019-11-28">475893.3575862689</value>
  </transaction>
  <transaction>
   <transaction-type code="3"></transaction-type>
   <transaction-date iso-date="2020-01-28"></transaction-date>
   <value currency="USD" value-date="2020-01-28">189466.4321313398</value>
  </transaction>
  <transaction>
   <transaction-type code="3"></transaction-type>
   <transaction-date iso-date="2021-01-28"></transaction-date>
   <value currency="USD" value-date="2021-01-28">128016.2220267761</value>
  </transaction>
  <crs-add>
   <other-flags code="1" significance="1"></other-flags>
  </crs-add>
  <sida:contribution xmlns:sida="http://sida.se/ns/contribution#"></sida:contribution>
 </iati-activity>
</iati-activities>
